4,000 Babies Prove Common Pain Meds Safe

Parents around the world just got some reassuring news about two medicines sitting in most bathroom cabinets.

A major New Zealand study tracked nearly 4,000 babies through their first year of life and found that acetaminophen (Tylenol) and ibuprofen (Advil) are incredibly safe to use. Neither medication increased the risk of eczema or bronchiolitis, a common respiratory illness in young children.

For years, earlier studies had raised concerns that acetaminophen given during infancy might be connected to eczema, asthma, or other health conditions later in childhood. Those worries kept many parents up at night, wondering if they were making the right choice when their baby had a fever.

This new research offers strong reassurance. Half the babies received acetaminophen when medication was needed for fever or pain, while the other half received ibuprofen. Parents tracked their children's health throughout the year, and researchers reviewed prescription information and hospital records.

The results were clear. About 16 percent of babies in the acetaminophen group developed eczema, compared with 15 percent in the ibuprofen group. Bronchiolitis affected about five percent of children in each group. These tiny differences weren't statistically significant.

"Our study found that paracetamol and ibuprofen are incredibly safe to use in young children," says lead researcher Professor Stuart Dalziel from the University of Auckland and Starship Children's Hospital. "These results give parents and health professionals high confidence to continue to use these important medications."

Serious side effects were uncommon, and researchers couldn't attribute any to either medication. This matters because acetaminophen and ibuprofen are among the most frequently prescribed or purchased medicines for babies worldwide.

Why This Inspires

This study represents something special: scientists taking parent concerns seriously enough to conduct the largest clinical trial involving children ever carried out in New Zealand. Rather than dismissing worries or relying on guesswork, researchers invested time and resources to provide real answers.

The PIPPA Tamariki study will continue following these children until age six, examining whether acetaminophen use connects to conditions like asthma, autism, or ADHD that can only be diagnosed reliably as children grow older. "We know that two-thirds of children who are wheezy at age three years don't develop asthma by age six," explains Dalziel. "Thus we need to wait until school age to ultimately test if paracetamol in the first year of life causes asthma."

For now, parents have solid evidence that reaching for fever medicine when their baby needs it is a safe choice, backed by the gold standard of medical research: a randomized controlled trial.